1. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor.
- Author
-
Katz D, Segal A, Alberton Y, Jurim O, Reissman P, Catane R, and Cherny NI
- Subjects
- Benzamides, Biopsy, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Drug Administration Schedule, Follow-Up Studies, Gastrectomy, Gastrointestinal Neoplasms diagnosis, Gastrointestinal Neoplasms pathology, Humans, Imatinib Mesylate, Intestinal Polyps diagnosis, Intestinal Polyps pathology, Israel, Male, Middle Aged, Neoplasm Invasiveness diagnostic imaging, Piperazines administration & dosage, Postoperative Period, Pyrimidines administration & dosage, Remission Induction methods, Splenectomy, Stromal Cells pathology, Tomography, Spiral Computed, Treatment Outcome, Gastrointestinal Neoplasms drug therapy, Neoadjuvant Therapy methods, Piperazines therapeutic use, Pyrimidines therapeutic use, Stromal Cells drug effects
- Abstract
We have evaluated the feasibility of the use of neoadjuvant imatinib mesylate in the management of unresectable localized gastrointestinal stromal tumors. In a pilot experience, two patients with unresectable gastrointestinal tumors were treated with neoadjuvant imatinib. Their treatment course and surgical outcomes are described. In both cases, the patient attained sufficient tumor regression to enable complete resection of tumor. We conclude that in the management of unresectable gastrointestinal stromal tumors, neoadjuvant administration of imatinib may facilitate sufficient tumor regression to facilitate subsequent tumor resection with curative intent.
- Published
- 2004
- Full Text
- View/download PDF